Opinion
Oct 20, 2026
Biotech has a translation problem
Biotech companies rarely suffer from a lack of expertise. More often, the challenge is turning years of scientific knowledge into a story that investors, partners and potential employees can quickly understand and act on. When the value of the science is hard to grasp, opportunities can be missed before a deeper conversation even begins. The challenge is to create clarity without losing the depth and nuance that make the science credible.
